• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 1, 2011

View Archived Issues

Centocor Licenses AVEO RON Antibodies for Potential $555M+

AVEO Pharmaceuticals Inc. licensed exclusive worldwide development and commercialization rights to the company's preclinical antibodies targeting the RON (Recepteur d'Origine Nantais) receptor to Centocor Ortho Biotech Inc., of Horsham, Pa., a wholly owned subsidiary of Johnson & Johnson, for $15 million up front, as much as $540 million in milestones and double-digit royalties on worldwide net sales. Read More

Optimer Hoping for 'Impactful' Launch with Dificid in CDAD

After a three-day weekend to digest the news of Optimer Pharmaceuticals Inc.'s approval for macrolide antibiotic Dificid (fidaxomicin), investors jumped on the San Diego-based firm's stock (NASDAQ:OPTR) Tuesday, which, trading at seven times its average volume, gained $1.53, or 11.8 percent, to close at $14.51. Read More

There Goes the Virtual Neighborhood for Biotechs

Facebook is forcing biotechs to get out of the neighborhood or get more friendly – a move that could set drug companies up for a potential run-in with the regulatory police. Read More

ESA Competition? Affymax Files Peginesatide NDA

Shares of Affymax Inc. have yet to recover from the beating they took about a year ago when Phase III data for peginesatide (formerly Hematide) fell short of investor expectations, but that hasn't stopped the Palo Alto, Calif.-based biotech and partner Takeda Pharmaceutical Co. Ltd. from moving forward with a new drug application (NDA). Read More

Financings Roundup

Excelimmune Inc., of Woburn, Mass., closed a Series B financing worth $10.5 million to advance its antibiotic candidate Staphguard. The drug is a human recombinant polyclonal antibody designed to target methicillin-resistant Staphylococcus aureus. The funds will also be used to improve the company's discovery platform and finish proof-of-principle work on its manufacturing system. Read More

Stock Movers

Read More

Other News To Note

Omeros Corp., of Seattle, reported it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) GPR27 and GPR173, which together with GPR85, an orphan that Omeros previously unlocked, form the Super Conserved Receptor Expressed in Brain (SREB) family, a unique and evolutionarily conserved family of orphan GPCRs thought to be critical in regulating neural integrity. Read More

Clinic Roundup

Vivus Inc., of Mountain View, Calif., presented several posters at the European Congress on Obesity in Istanbul, Turkey, including data that showed Qnexa (phentermine/topiramate) reduced progression to Type II diabetes and improved glycemic status in patients defined as prediabetics at baseline. In the prediabetic population from the CONQUER study, significantly more Qnexa-treated patients achieved normal blood sugar levels (p = 0.0016) and significantly more patients in the placebo arm progressed to Type II diabetes (p = 0.0253). Qnexa was rejected by the FDA last year, but Vivus plans to resubmit a new drug application in the fourth quarter of this year. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe